Roche to present new data at the American Society of Hematology 2020 Annual Meeting

Nov. 6, 2020

Roche announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held December 5-8, 2020, according to a press release from the company.

Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukemia, multiple myeloma (MM) and hemophilia A, these data highlight the strength and breadth of Roche’s hematology portfolio and pipeline, and commitment to developing innovative treatment solutions for patients in need.

Building on its 20-year experience in antibody engineering, Roche is exploring mechanisms of action for immunotherapies including T-cell engaging bispecific antibodies. Data on three investigational bispecifics will be presented, including:

•  Progress from Roche’s CD20xCD3 bispecific antibody development program, including updated results for mosunetuzumab in relapsed or refractory (R/R) follicular lymphoma and early data in first-line diffuse large B-cell lymphoma (DLBCL). Additionally, data demonstrating high response rates with step-up dosing of glofitamab in people with R/R NHL will be presented.

•  First clinical safety, efficacy and biomarker data from cevostamab (BFCR4350A), a first-of-its-kind FcRH5xCD3 bispecific antibody targeting FcRH5 on myeloma cells and CD3 on T-cells, will be presented, with initial results from the ongoing phase I GO39775 dose-escalation study in people with heavily pre-treated R/R MM

Roche will also be sharing longer-term data, including results on novel clinical trial endpoints, that support the known efficacy and safety of its established medicines, including:

• Three-year follow-up data from the phase III HAVEN study program (HAVEN 1-4 studies), reinforcing the efficacy and safety profile of Hemlibra (emicizumab) in people with hemophilia A with and without factor VIII inhibitors.

• Results from the first interim analysis of the European Haemophilia Safety Surveillance database, examining real-world data to monitor the ongoing safety of Hemlibra in people with hemophilia A with and without factor VIII inhibitors.

• Results on fixed-duration, chemotherapy-free combinations in chronic lymphocytic leukemia (CLL), including five-year analysis of the phase III MURANO study, investigating Venclexta/Venclyxto (venetoclax) plus MabThera/Rituxan (rituximab) in R/R CLL, with updates on minimal residual disease and long-term outcomes analysis. Venclexta/Venclyxto is being developed by AbbVie and Roche.

• Updated results from the phase Ib/II randomised GO29365 study of fixed-duration Polivy (polatuzumab vedotin), plus bendamustine and MabThera/Rituxan, in people with R/R DLBCL, including preliminary results from a single-arm extension cohort of 106 additional patients. 

Visit Roche for more news